Novartis Wins Jury Verdict Over Zometa's Bone Death Risk
A New Jersey jury on Wednesday returned with a verdict for Novartis Pharmaceuticals Corp. in centralized litigation over its bone-strengthening drug Zometa, finding after a 13-day trial that the company did...To view the full article, register now.
Already a subscriber? Click here to view full article